Search

Displaying results 491 - 500 of 4584 in total
  1. Drug

    Eucalyptol

    go.drugbank.com/drugs/DB03852
    ApprovedInvestigationalNutraceutical

    It controls airway mucus hypersecretion and asthma via anti-inflammatory cytokine inhibition. Eucalyptol is an effective treatment for nonpurulent rhinosinusitis.

    Mixtures: Shaping without workout, POMADA VILA
  2. Drug

    Lebrikizumab

    go.drugbank.com/drugs/DB11914
    ApprovedInvestigational

    years and older with a body weight of at least 40 kg. … [L49404] Lebrikizumab was also approved by the FDA on September 13, 2024.[L51379]

  3. Drug

    Aminophenazone

    go.drugbank.com/drugs/DB01424
    ApprovedWithdrawn

    Aminophenazone is a pyrazolone with analgesic, anti-inflammatory, and antipyretic properties that carries a risk of agranulocytosis. In biomedical applications, radiolabelled (13C-labeled) aminophenazone has been used in breath tests to ...

  4. Drug

    Upadacitinib

    go.drugbank.com/drugs/DB15091
    ApprovedInvestigational

    [A189168] To reduce dose-related toxicity (as seen with some pan-JAK inhibitors) without significantly affecting efficacy, more selective JAK1 inhibitors, upadacitinib and [filgotinib], were developed. … More recently, it has also been approved for the treatment of giant cell arteritis in adults and active polyarticular juvenile idiopathic arthritis in patients aged 2 years and older.[L10896]

  5. Drug

    Oxymorphone

    go.drugbank.com/drugs/DB01192
    ApprovedVet approved

    An opioid analgesic with actions and uses similar to those of morphine, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an ...

  6. Drug

    Iobenguane sulfate I-123

    go.drugbank.com/drugs/DB09546
    Approved

    Iobenguane sulfate I-123 is a radiopharmaceutical used in gamma-scintigraphy of adrenergically inervated tissues [FDA Label].

  7. Drug

    Belzutifan

    go.drugbank.com/drugs/DB15463
    ApprovedInvestigational

    by Merck in 2019). … [L36000] It was later approved for the treatment of locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL) in patients aged 12 years and older.[L49271]

  8. Drug

    Daptomycin

    go.drugbank.com/drugs/DB00080
    ApprovedInvestigational

    [A231384] Early work on developing daptomycin was abandoned due to observed myopathy but was resumed in 1997 when Cubist Pharmaceuticals Inc. licensed daptomycin; it was found that a once-daily dosing … [A231379] Daptomycin was approved by the FDA on September 12, 2003, and is marketed under the name CUBICIN® by Cubist Pharmaceuticals LLC (Merck & Co.).[L32534]

  9. Drug

    Omidubicel

    go.drugbank.com/drugs/DB17132
    ApprovedInvestigational

    [L46048,L46058] In December 2025, the indication was expanded to include adults and pediatric patients six years and older with severe aplastic anemia (SAA). [L46048,L54688] … [A258958] In April 2023, the FDA approved the use of omidubicel in adults and pediatric patients 12 years and older with blood cancers planned for umbilical cord blood transplantation following a myeloablative

  10. Drug

    Apadamtase alfa

    go.drugbank.com/drugs/DB15164
    ApprovedInvestigational

    Thrombotic thrombocytopenic purpura (TTP) is a rare blood clotting disorder characterized by thrombocytopenia, microangiopathic hemolytic anemia, and various degrees of organ damage. … [A262071] Apadamtase alfa, sold under the brand name Adzynma (ADAMTS13, recombinant-krhn), was approved by the FDA in November 2023 for use as an enzyme replacement therapy in patients with cTTP.